https://smallcaps.com.au/article/invex-therapeutics-fda-meeting-phase-iii-trial-presendin-treatment-idiopathic-intracranial-hypertension
Invex Therapeutics granted FDA meeting to advance Presendin phase III trial for treating idiopathic...
Apr 22, 2021 - Clinical-stage biopharmaceutical company Invex Therapeutics (ASX: IXC) has been granted a meeting with the US Food and Drug Administration to discuss the...
phase iii trialinvex therapeuticsgrantedfdameeting